Kidney Week

Abstract: FR-PO0545

Prevalence of CKD in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Session Information

• CKM: Clinical - Trials, Epidemiology, and Biomarkers
  October 23, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Cardiovascular-Kidney-Metabolic Health

• 602 Cardiovascular-Kidney-Metabolic Health: Clinical

Authors

• Delgado Avila, Brenda Guadalupe, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Brenda Guadalupe Delgado Avila

• Mejia, Juan Manuel, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Juan Manuel Mejia, MD, PhD

• Rivero Otamendi, Emiliano, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Emiliano Rivero Otamendi

• Santos, Julio Cesar, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Julio Cesar Santos, MD

• Matías Martinez, Melvin Barish, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Melvin Barish Matías Martinez, MD

• Navarro Sanchez, Valeria, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Valeria Navarro Sanchez, MD

• Echeverria, Raymundo David Valdez, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Raymundo David Valdez Echeverria

• Sánchez-Mejía, Daniela Edith, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, CDMX, Mexico

Daniela Edith Sánchez-Mejía

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent and frequently coexists with cardiometabolic risk factors associated with chronic kidney disease (CKD). Although MASLD has been linked to incident CKD and kidney failure, data from Latin American cohorts remain limited. We evaluated the prevalence of kidney disease markers and their association with hepatic steatosis and fibrosis in patients with MASLD.

Methods

We performed a cross-sectional analysis of patients with established MASLD evaluated at a tertiary referral center in Mexico City. Demographic, metabolic, hepatic, and kidney parameters were analyzed. Liver steatosis and fibrosis were assessed by elastography. Kidney disease markers included creatinine-Cystatin C estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). Albuminuria was defined as UACR ≥30 mg/g, reduced kidney function as eGFR <60 mL/min/1.73 m2. Associations between liver fibrosis, steatosis, albuminuria, and eGFR were explored using comparative and correlation analyses.

Results

A total of 107 patients with MASLD were included. Diabetes mellitus was present in 97 of 106 patients with available data (91.5%), reflecting a high cardiometabolic risk burden. Albuminuria was present in 40.0% of patients, while reduced eGFR was observed in 3.8%. Overall, 41.5% of the cohort had at least one kidney disease marker. Most kidney involvement was driven by moderately increased albuminuria rather than reduced eGFR. In exploratory analyses, liver fibrosis stage and steatosis grade were not significantly associated with albuminuria or eGFR. Similarly, no significant trend was observed between increasing hepatic fibrosis severity and higher UACR or lower eGFR.

Conclusion

In this MASLD cohort with high diabetes prevalence, kidney disease markers were frequent, mainly due to albuminuria, whereas reduced eGFR was uncommon. No significant association was observed between liver fibrosis or steatosis severity and albuminuria or eGFR in this preliminary cross-sectional analysis. These findings support systematic kidney screening with both eGFR and UACR in patients with MASLD, particularly in those with high cardiometabolic burden, and highlight the need for longitudinal studies to determine whether MASLD contributes to kidney disease progression in this population.